Vizgen
Cambridge
About Vizgen
Vizgen is a life sciences technology company that develops advanced spatial biology and multi-omics platforms to help scientists map and understand gene and protein expression within intact tissues at single-cell resolution. Its core technologies include MERFISH 2.0, a high-plex spatial transcriptomics method that enables detailed visualization of thousands of RNA molecules while preserving spatial context, and the MERSCOPE imaging platforms that support comprehensive spatial genomics experiments with high sensitivity and reproducibility. Complementing transcriptomic data, Vizgen’s InSituPlex® multiplex immunofluorescence proteomics assays and STARVUE™ AI-driven image analysis tools enable quantitative protein detection and the integration of RNA-protein insights, empowering researchers to explore complex biological systems, such as tumor microenvironments, immune landscapes, and tissue architecture. Vizgen’s platforms are designed to accelerate breakthroughs in understanding disease mechanisms and advancing drug discovery by enabling unprecedented views into cellular organization and molecular interactions within tissues.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $187.7M
- Funding stage: Late Stage Venture
- Last round: Series E (Jan 2026)
- Website: vizgen.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/vizgen-61862 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.